vs
Side-by-side financial comparison of Gaming & Leisure Properties, Inc. (GLPI) and Bio-Techne (TECH). Click either name above to swap in a different company.
Gaming & Leisure Properties, Inc. is the larger business by last-quarter revenue ($420.0M vs $295.9M, roughly 1.4× Bio-Techne). Gaming & Leisure Properties, Inc. runs the higher net margin — 57.0% vs 12.8%, a 44.2% gap on every dollar of revenue. On growth, Gaming & Leisure Properties, Inc. posted the faster year-over-year revenue change (6.3% vs -6.4%). Over the past eight quarters, Gaming & Leisure Properties, Inc.'s revenue compounded faster (5.0% CAGR vs 4.2%).
Gaming and Leisure Properties, Inc. is a real estate investment trust (REIT) specializing in casino properties, based in Wyomissing, Pennsylvania. It was formed in November 2013 as a corporate spin-off from Penn National Gaming. The company owns 62 casino properties, all of which are leased to other companies.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
GLPI vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $420.0M | $295.9M |
| Net Profit | $239.4M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 79.4% | 18.4% |
| Net Margin | 57.0% | 12.8% |
| Revenue YoY | 6.3% | -6.4% |
| Net Profit YoY | 40.5% | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $420.0M | — | ||
| Q4 25 | $407.0M | $295.9M | ||
| Q3 25 | $397.6M | — | ||
| Q2 25 | $394.9M | $317.0M | ||
| Q1 25 | $395.2M | $316.2M | ||
| Q4 24 | $389.6M | $297.0M | ||
| Q3 24 | $385.3M | $289.5M | ||
| Q2 24 | $380.6M | $306.1M |
| Q1 26 | $239.4M | — | ||
| Q4 25 | $275.4M | $38.0M | ||
| Q3 25 | $241.2M | — | ||
| Q2 25 | $151.4M | $-17.7M | ||
| Q1 25 | $165.2M | $22.6M | ||
| Q4 24 | $223.6M | $34.9M | ||
| Q3 24 | $184.7M | $33.6M | ||
| Q2 24 | $208.3M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | 79.4% | — | ||
| Q4 25 | 89.3% | 18.4% | ||
| Q3 25 | 84.8% | — | ||
| Q2 25 | 61.3% | -7.5% | ||
| Q1 25 | 65.5% | 12.2% | ||
| Q4 24 | 79.1% | 16.0% | ||
| Q3 24 | 70.4% | 13.8% | ||
| Q2 24 | 77.1% | 15.0% |
| Q1 26 | 57.0% | — | ||
| Q4 25 | 67.6% | 12.8% | ||
| Q3 25 | 60.7% | — | ||
| Q2 25 | 38.4% | -5.6% | ||
| Q1 25 | 41.8% | 7.1% | ||
| Q4 24 | 57.4% | 11.7% | ||
| Q3 24 | 47.9% | 11.6% | ||
| Q2 24 | 54.7% | 13.3% |
| Q1 26 | — | — | ||
| Q4 25 | $0.96 | $0.24 | ||
| Q3 25 | $0.85 | — | ||
| Q2 25 | $0.54 | $-0.11 | ||
| Q1 25 | $0.60 | $0.14 | ||
| Q4 24 | $0.79 | $0.22 | ||
| Q3 24 | $0.67 | $0.21 | ||
| Q2 24 | $0.77 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.5M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $5.0B | $2.0B |
| Total Assets | $13.8B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $274.5M | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | $560.8M | $177.5M | ||
| Q3 24 | $560.8M | $187.5M | ||
| Q2 24 | $560.8M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $7.2B | $260.0M | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $6.9B | $346.0M | ||
| Q1 25 | $6.9B | $330.0M | ||
| Q4 24 | $7.7B | $300.0M | ||
| Q3 24 | $7.4B | $300.0M | ||
| Q2 24 | $6.6B | $319.0M |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.6B | $2.0B | ||
| Q3 25 | $4.6B | — | ||
| Q2 25 | $4.6B | $1.9B | ||
| Q1 25 | $4.2B | $2.0B | ||
| Q4 24 | $4.3B | $2.1B | ||
| Q3 24 | $4.3B | $2.1B | ||
| Q2 24 | $4.1B | $2.1B |
| Q1 26 | $13.8B | — | ||
| Q4 25 | $12.9B | $2.5B | ||
| Q3 25 | $12.8B | — | ||
| Q2 25 | $12.5B | $2.6B | ||
| Q1 25 | $12.1B | $2.6B | ||
| Q4 24 | $13.1B | $2.7B | ||
| Q3 24 | $12.7B | $2.7B | ||
| Q2 24 | $11.8B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 1.56× | 0.13× | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | 1.51× | 0.18× | ||
| Q1 25 | 1.63× | 0.16× | ||
| Q4 24 | 1.81× | 0.14× | ||
| Q3 24 | 1.74× | 0.14× | ||
| Q2 24 | 1.60× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLPI
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
